7 completed, 1 recruiting. 8 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 7, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Recruiting 1 |
Follow Translocation, Genetic: new trials by email Literature Review of Translocation, Genetic trials Research Report on Translocation, Genetic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies CD19/CD22 CAR T-Cells, Fludarabine, Cyclophosphamide - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, B Cell | Phase 1 | Completed | National Cancer Institute (NCI) | 54 | 2018-03-26 | 2025-06-04 |
| Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2012-08-08 | 2020-03-05 |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Melphalan, Fludarabine, Mycophenolate mofetil - Blood And Marrow Transplantation, Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2012-07-13 | 2017-04-28 |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI Radotinib - Leukemia, Leukemia, Myeloid | Phase 1 / Phase 2 | Completed | Il-Yang Pharm. Co., Ltd. | 85 | 2008-07-01 | 2018-08-29 |
| Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Imatinib/Acetaminophen - Chronic Myeloid Leukemia (CML) | Phase 1 | Completed | Novartis Pharmaceuticals | 12 | 2006-11-01 | 2016-04-21 |
| Effect of Food on Bioavailability of Modified Release Formulations of Imatinib imatinib - Healthy | Phase 1 | Completed | Novartis | 32 | 2006-09-01 | 2016-04-05 |
| Effect of Food on Bioavailability of a Modified Release Formulation of Imatinib imatinib - Healthy | Phase 1 | Completed | Novartis Pharmaceuticals | 16 | 2006-06-01 | 2016-04-05 |
Philadelphia Chromosome (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (6) · Leukemia (3) · Lymphoma (3) · Lymphoma, Non-Hodgkin (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Leukemia, B-Cell (2) · Lymphoma, B-Cell (2) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Histiocytosis, Langerhans-Cell (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid (1)
Chromosome Aberrations (8) · Hemic and Lymphatic Diseases (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Hematologic Diseases (7) · Bone Marrow Diseases (6) · Chronic Disease (6) · Disease Attributes (6) · Myeloproliferative Disorders (6) · Leukemia (5) · Leukemia, Myeloid (5) · Immune System Diseases (3)
Imatinib Mesylate (3) · fludarabine (3) · Acetaminophen (2) · Cyclophosphamide (2) · fludarabine phosphate (2) · 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide (1) · Antiemetics (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Blood Component Removal (1) · Blood Specimen Collection (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Clofarabine (1) · Diphenhydramine (1)
M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · Novartis Pharmaceuticals (2) · Il-Yang Pharm. Co., Ltd. (1) · Novartis (1)
United States (4) · South Korea (2) · India (1) · Thailand (1)
Elizabeth Shpall, MD (1) · IL-yang Pharm (1) · Jorge Cortes, MD (1) · Nirali N Shah, M.D. (1) · Sara K Silbert, M.D. (1)
PMID 24705186, PMID 25778529, PMID 34687939, PMID 34889384, PMID 35605184, PMID 37486616, PMID 38376944, PMID 42248607
P01CA148600 (1)